Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas

A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma

(2018) Ruichao Chai et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients

(2017) Guoqiang Yuan et al.   JOURNAL OF NEURO-ONCOLOGY

Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter

(2017) Jinho Kim et al.   JOURNAL OF NEUROSURGERY

Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas

(2017) Zheng Zhao et al.   Scientific Data

CGCG clinical practice guidelines for the management of adult diffuse gliomas

(2016) Tao Jiang et al.   CANCER LETTERS

Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma

(2016) Giovanni Brigliadori et al.   JOURNAL OF NEURO-ONCOLOGY

Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma

(2016) Wen Cheng et al.   JOURNAL OF NEUROSURGERY

The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis

(2016) Hailong Zhao et al.   World Journal of Surgical Oncology

Digital PCR quantification ofMGMTmethylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer

(2015) L. Barault et al.   ANNALS OF ONCOLOGY

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions

(2015) Michal Bienkowski et al.   CLINICAL NEUROPATHOLOGY

TheMGMTpromoter SNP rs16906252 is a risk factor forMGMTmethylation in glioblastoma and is predictive of response to temozolomide

(2015) Robert W. Rapkins et al.   NEURO-ONCOLOGY

A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients

(2015) Wen Cheng et al.   Oncotarget

Identification of a 6-Cytokine Prognostic Signature in Patients with Primary Glioblastoma Harboring M2 Microglia/Macrophage Phenotype Relevance

(2015) Jinquan Cai et al.   PLoS One

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients

(2014) Véronique Quillien et al.   JOURNAL OF NEURO-ONCOLOGY

MGMT testing—the challenges for biomarker-based glioma treatment

(2014) Wolfgang Wick et al.   Nature Reviews Neurology

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

(2013) W. Wick et al.   NEUROLOGY

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g

(2012) Véronique Quillien et al.   CANCER

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

(2012) Annette Håvik et al.   Journal of Translational Medicine

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

(2012) W. Zhang et al.   NEURO-ONCOLOGY

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts

(2011) Deborah S. Malley et al.   ACTA NEUROPATHOLOGICA

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

(2011) Guido Reifenberger et al.   INTERNATIONAL JOURNAL OF CANCER

MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations

(2011) Shani Mulholland et al.   INTERNATIONAL JOURNAL OF CANCER

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

(2009) J Dunn et al.   BRITISH JOURNAL OF CANCER

MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

(2009) Lucie Karayan-Tapon et al.   JOURNAL OF NEURO-ONCOLOGY

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

(2009) Sibille Everhard et al.   NEURO-ONCOLOGY